Harbor Capital Advisors Inc. Buys Shares of 59,801 ADMA Biologics Inc $ADMA

Harbor Capital Advisors Inc. purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 59,801 shares of the biotechnology company’s stock, valued at approximately $877,000.

A number of other institutional investors also recently modified their holdings of the company. State Street Corp raised its stake in ADMA Biologics by 5.6% during the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after buying an additional 637,727 shares during the last quarter. Geode Capital Management LLC grew its holdings in ADMA Biologics by 4.3% during the 2nd quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company’s stock worth $107,691,000 after acquiring an additional 245,309 shares during the period. American Century Companies Inc. raised its position in shares of ADMA Biologics by 8.4% in the 2nd quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after acquiring an additional 358,627 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of ADMA Biologics by 8.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,320,251 shares of the biotechnology company’s stock valued at $59,366,000 after purchasing an additional 271,305 shares during the period. Finally, Thrivent Financial for Lutherans lifted its stake in shares of ADMA Biologics by 78.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company’s stock valued at $60,373,000 after purchasing an additional 1,453,924 shares during the period. 75.68% of the stock is owned by institutional investors.

ADMA Biologics Price Performance

ADMA stock opened at $19.28 on Friday. The stock has a market capitalization of $4.59 billion, a PE ratio of 22.42 and a beta of 0.43. The company’s 50-day moving average is $17.43 and its 200-day moving average is $17.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.13 and a quick ratio of 3.65. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The firm’s revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.15 EPS. Equities research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.